Vertex Pharmaceuticals Incorporated (VRTX) COO Ian F. Smith Sells 6,405 Shares of Stock
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) COO Ian F. Smith sold 6,405 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $150.00, for a total transaction of $960,750.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) opened at $151.31 on Wednesday. Vertex Pharmaceuticals Incorporated has a 52 week low of $71.46 and a 52 week high of $167.85. The company has a quick ratio of 3.14, a current ratio of 3.28 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $37,677.46, a P/E ratio of 248.30, a price-to-earnings-growth ratio of 3.78 and a beta of 1.63.
Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.04 by $0.49. Vertex Pharmaceuticals had a return on equity of 9.23% and a net margin of 8.53%. The business had revenue of $578.20 million during the quarter, compared to the consensus estimate of $522.07 million. During the same period in the prior year, the company posted $0.16 EPS. The firm’s revenue for the quarter was up 39.7% compared to the same quarter last year. equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 0.72 earnings per share for the current fiscal year.
Several research firms have commented on VRTX. Royal Bank Of Canada reissued a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Friday, October 27th. Needham & Company LLC reissued a “buy” rating and set a $195.00 price target on shares of Vertex Pharmaceuticals in a research note on Friday, October 27th. Robert W. Baird restated a “buy” rating on shares of Vertex Pharmaceuticals in a report on Friday, October 27th. HC Wainwright restated a “hold” rating and issued a $85.00 target price on shares of Vertex Pharmaceuticals in a report on Thursday, October 26th. Finally, Maxim Group restated a “buy” rating and issued a $195.00 target price on shares of Vertex Pharmaceuticals in a report on Thursday, October 26th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $173.15.
Hedge funds have recently bought and sold shares of the business. Jennison Associates LLC raised its holdings in shares of Vertex Pharmaceuticals by 253.8% during the 2nd quarter. Jennison Associates LLC now owns 5,055,122 shares of the pharmaceutical company’s stock worth $651,454,000 after acquiring an additional 3,626,368 shares in the last quarter. Old Mutual Global Investors UK Ltd. raised its holdings in Vertex Pharmaceuticals by 1,384.7% during the 2nd quarter. Old Mutual Global Investors UK Ltd. now owns 1,195,455 shares of the pharmaceutical company’s stock valued at $154,058,000 after buying an additional 1,114,939 shares during the period. Assenagon Asset Management S.A. raised its holdings in Vertex Pharmaceuticals by 9,422.3% during the 3rd quarter. Assenagon Asset Management S.A. now owns 893,380 shares of the pharmaceutical company’s stock valued at $135,829,000 after buying an additional 883,998 shares during the period. AJO LP purchased a new stake in Vertex Pharmaceuticals during the 2nd quarter valued at $71,956,000. Finally, Vanguard Group Inc. grew its position in Vertex Pharmaceuticals by 3.1% in the 2nd quarter. Vanguard Group Inc. now owns 16,979,872 shares of the pharmaceutical company’s stock valued at $2,188,196,000 after acquiring an additional 504,982 shares during the last quarter. Institutional investors and hedge funds own 93.06% of the company’s stock.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Stock Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related stocks with our FREE daily email newsletter.